Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Guardant Health, Inc.

< Previous 1 2 3 4 5 6 Next >
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Named to TIME100 Most Influential Companies
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Tickers GH
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
From Guardant Health, Inc.
Via Business Wire
Tickers GH
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Tickers GH HKMPY OTC
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.